Nephrotoxicity Evaluation on Cisplatin Combined with 5-HT₃ Receptor Antagonists: A Retrospective Study

Table 2

Risk ratio in multivariable analysis of potential predisposing factors for cisplatin-induced nephrotoxicity ( = 270).

Factor	Risk ratio	95% Cl	value
Age (≥60 vs. ≤60)	0.131	0.036–0.326	0.202
Sex (male vs. female)	0.057	1.79–3.83	0.474
PS (2 vs. 0 or 1)	0.119	2.77–5.07	0.542
Weight	0.287	0.015–11.22	0.051
Baseline Cr	0.11	4.74–7.69	0.632
Cisplatin dose	0.057	2.40–7.46	<0.001
Tumor type
Esophageal cancer	1.000
Lung cancer	0.845	5.56–8.01	0.717
Gastric cancer	1.316	4.45–10.46	0.400
Cervical cancer	1.119	2.21–6.10	0.349
Endometrial cancer	0.838	3.38–12.24	0.238
Bronchial cancer	0.870	0.05–7.66	0.053